

Steve Sisolak  
Governor  
Richard Whitley, MS  
Director



DEPARTMENT OF  
HEALTH AND HUMAN SERVICES  
Division of Health Care Financing and Policy  
*Helping people. It's who we are and what we do.*



Suzanne Bierman, JD, MPH  
Administrator

February 19, 2021

Brenda Erdoes  
Director, Legislative Council Bureau  
401 South Carson Street  
Carson City, Nevada 89701

Dear Ms. Erdoes:

The State Fiscal Year 2020 report concerning the financial effects of obtaining prescription drugs through health plan benefits submitted by the Division of Health Care Financing and Policy (DHCFP, Nevada Medicaid) of the Department of Health and Human Services (DHHS) satisfies the requirements of Senate Bill 378 from the 2019 Legislative Session:

- Nevada Revised Statutes Chapter 422.4025, Section 6 requires DHHS to submit a report to the Director of the Legislative Council Bureau for transmittal to the Legislature in odd-numbered years and to the Legislative Commission in even-numbered years.

If you have any questions concerning the report, please contact David Olsen at (775) 684-3623 or via e-mail at [david.olsen@dhcfp.nv.gov](mailto:david.olsen@dhcfp.nv.gov).

Sincerely,

A handwritten signature in black ink that reads "Suzanne Bierman".

Suzanne Bierman, JD, MPH  
Administrator

Cc: Richard Whitley, Director, DHHS  
Beth Slamowitz, Senior Advisor on Pharmacy, DHHS  
DuAne Young, Deputy Administrator over Medical Programs and Community Based Services, DHCFP  
Cody Phinney, Deputy Administrator over Compliance, DHCFP  
Phillip Burrell, Fiscal Deputy Administrator, DHCFP  
David Olsen, Pharmacy Chief, DHCFP

## State Fiscal Year 2020 Supplemental Rebate Agreement Reporting

Nevada Revised Statutes Chapter 422.4025, Section 6 requires reporting concerning the financial effects of obtaining prescription drugs through health plan benefits to be posted on the Department of Health and Human Services website.

In Nevada, three managed care organizations enter into rebate agreements to purchase prescription drugs for health plans under the Medicaid program. A pharmacy benefit manager enters into rebate agreements on behalf of the fee-for-service Medicaid program. A summary of these agreements is provided in the table below.

**Table 1**

| <b>Summary of Supplemental Rebate Agreements for Health Plans in SFY2020</b> |   |                        |
|--|---|------------------------|
| <b>Health Plan</b>   | <b>Number of Manufacturers Under Contract</b> | <b>Contract Value</b>  |
| Anthem   | 130   | \$3,945,103.51         |
| Health Plan of Nevada  | 46  | \$8,603,399.40         |
| SilverSummit Healthplan  | 106   | \$945,758.73           |
| <b>Total Contract Value of All Health Plans</b>                              | -   | <b>\$13,494,261.64</b> |
| Fee-for-Service Medicaid   | 36  | \$7,661,308.26         |
| <b>Total Contract Value for all of Nevada Medicaid</b>                       | -   | <b>\$21,155,569.90</b> |

Each of these managed care organizations has provided additional information specific to their health plan's supplemental rebate agreements in the following order:

- Anthem (pages 2 – 13)
- Health Plan of Nevada (pages 14-17)
- SilverSummit Healthplan (pages 18-25)

Additional information specific to supplemental rebate agreements related to prescription drugs for fee-for-service Medicaid recipients is provided by a single pharmacy benefit manager vendor:

- Optum Rx (pages 26- 32)

Please refer to the following pages of this document for details regarding manufacturer names, contract term dates, and contract values for individual, deidentified supplement rebate agreements.

Nevada Medicaid receives rebates on prescription drugs under two different programs. The Federal Medicaid Drug Rebate Program (MDRP) provides for Federally mandated rebates. The Nevada Medicaid Supplemental Rebate Program (NMSRP), pursuant to paragraph (b) of subsection 1 in section 31.4 of Senate Bill 378. (SB378), provides for Nevada-specific rebates that are in addition, or supplement, the Federally mandated rebates.

Created by the Omnibus Reconciliation Act of 1990 (OBRA 1990), the MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers must enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal unit rebate amount (URA) are set out by Federal statute.

In addition to the Federal rebate under the NDRA, state Medicaid agencies have the availability to collect additional rebates from manufacturers (e.g., supplemental). As set out above, the supplemental rebate program for Nevada Medicaid operates pursuant to SB378. The supplemental rebate does not reduce what is being paid under the NDRA, but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists.

The NMSRP has been in effect since January 1, 2012. The SRAs are between the manufacturers and the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP). Generally, the SRAs are in effect for one calendar year beginning on Jan 31<sup>st</sup> and terminating on Dec 31<sup>st</sup>. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes (NDC) released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-Dec 31<sup>st</sup> end date, such as a product moving to non-preferred status or to coincide with planned Silver State Scripts Board (SSSB) review.

During State Fiscal Year 2020, the rebates negotiated under the NMSRP only applied to Medicaid fee-for-service (FFS) utilization. The other entities, authorized under SB378 to participate in the Medicaid FFS PDL, did not elect to participate.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- “Percentage of WAC” — set percentage of the drug’s published wholesale acquisition cost (WAC).
- “Guaranteed Net Unit Price” (GNUP) WAC minus the Federal URA minus the GNUP.

Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc., an independent licensee of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

- In the event a drug’s WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
- Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer’s SRA with Anthem Blue Cross Blue Shield Healthcare Solutions.

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing-related terms and conditions.

Anthem had 71 (222) SRAs in place that were in effect during a portion of State Fiscal Year 2020 (July 1, 2019 – June 30, 2020) (hereinafter referred to as SFY 2020). Table 1 below summarizes the agreements:

Table 1 Column Definitions:

- Number of Contracts — The count of signed SRAs that were in force during some period within SFY 2020.
- Number of Manufacturers Under Contract — The count of unique manufacturers with a signed SRA in force during some period within SFY 2020.
- SFY 2020 Amount Anthem Medicaid Paid Providers for Products Under Contract During Contract Term — The amount Anthem Medicaid paid to providers for drugs subject to a manufacturer’s SRA during SFY 2020.
  - Example: Drug “A” was subject to an SRA from 1/1/2019 to 12/31/2019, but not under an agreement in 2020. This column would include the amount Medicaid paid to providers for Drug “A” for claims paid from 7/1/2019 to 12/31/2019.
- Contract Value During SFY 2020 — The supplemental rebate amount invoiced during SFY 2020 to manufacturers for drugs subject to SRAs.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products — The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

| Summary of Anthem Supplemental Rebate Agreements in Place during SFY 2020 |  |   |                                |  |
|---|--|---|--------------------------------|--|
| Number of Contracts   | Number of Manufacturers Under Contract | SFY 2020 Amount Anthem Medicaid Paid Providers for Products Under Contract During Contract Term | Contract Value During SFY 2020 | Supplemental Rebate Percentage of Drug Spend for Contracted Products |
| 217   | 130                                    | \$81,633,838.14   | \$3,945,103.51                 | 4.83%  |

Table 2 below lists the SRAs in place during SFY 2020. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name — The name of the entity the State has contracted within the SRA
- Contract Term — The effective and termination dates of the SRA

Table 2

| Anthem Supplemental Rebate Agreements in Place during SFY 2020 |                      |
|--|----------------------|
| Manufacturer Name  | Contract Term        |
| ABBOTT DIABETES CARE   | 10/1/2013-12/31/2019 |
| ABBOTT DIABETES CARE   | 1/1/2020-12/31/2022  |
| ABBVIE INC   | 1/1/2017-12/31/9999  |
| ACORDA THERAPEUTICS INC  | 1/1/2016-12/31/2019  |
| ACORDA THERAPEUTICS INC  | 1/1/2020-12/31/2021  |
| ACTELION PHARMACEUTICALS                                       | 7/1/2015-12/31/2019  |
| ADAPT PHARMA INC   | 7/1/2016-12/31/2019  |
| ADAPT PHARMA INC   | 1/1/20-12/31/9999    |
| AERIE  | 4/1/2018-12/31/2019  |
| AERIE  | 1/1/2020-12/31/9999  |
| AKORN, INC   | 1/1/2014-12/31/2019  |
| AKRIMAX PHARMACEUTICALS LLC                                    | 7/1/2017-12/31/2019  |
| ALKERMES INC   | 4/1/2016-12/31/2019  |
| ALKERMES INC   | 4/1/2020-12/31/2025  |
| ALLERGAN PHARM   | 1/1/2018-12/31/2019  |
| ALLERGAN PHARM   | 1/1/2020-12/31/9999  |
| AMAG PHARMACEUTICALS, INC                                      | 7/1/2013-12/31/2019  |
| AMAG PHARMACEUTICALS, INC                                      | 1/1/2020-12/31/9999  |
| AMARIN   | 7/1/2015-12/31/2019  |
| AMARIN   | 1/1/2020-12/31/9999  |
| AMGEN  | 4/1/2014-12/31/2019  |
| AMGEN  | 1/1/2020-12/31/2022  |
| ANTARES PHARMA INC   | 4/1/2015-12/31/2019  |
| ANTARES PHARMA INC   | 1/1/2020-12/31/9999  |
| AQUA PHARMACEUTICALS   | 4/1/2016-12/31/2019  |
| AQUA PHARMACEUTICALS   | 1/1/2020-3/31/2022   |
| ARBOR  | 1/1/2012-12/31/2019  |

| ARBOR  | 1/1/2020-12/31/2021  |
|--|----------------------|
| ARKRAY USA INC   | 10/1/2013-12/31/2019 |
| ARKRAY USA INC   | 1/1/2020-12/31/2022  |
| ASEGUA   | 1/1/2019-12/31/2019  |
| ASEGUA   | 1/1/2020-12/31/9999  |
| ASSERTIO   | 1/1/2019-12/31/2019  |
| Anthem Nevada Supplemental Rebate Agreements in Place during SFY<br>2020 |                      |
| Manufacturer Name  | Contract Term        |
| ASSERTIO   | 1/1/2020-12/31/9999  |
| ASTELLAS PHARMA US   | 1/1/2018-12/31/2019  |
| ASTELLAS PHARMA US   | 1/1/2020-12/31/9999  |
| ASTRA ZENECA   | 4/1/2014-12/31/2019  |
| ASTRA ZENECA   | 1/1/2020-12/31/9999  |
| AVANIR PHARMACEUTICALS   | 1/1/2014-12/31/2019  |
| AVANIR PHARMACEUTICALS   | 1/1/2020-12/31/2023  |
| AVION PHARMACEUTICALS  | 1/1/2013-12/31/2019  |
| AVION PHARMACEUTICALS  | 1/1/2020-12/31/9999  |
| BAYER  | 1/1/2017-12/31/2019  |
| BAYER  | 1/1/2020-12/31/2022  |
| BAYER DIAGNOSTICS  | 10/1/2013-12/31/2019 |
| BAYER DIAGNOSTICS  | 1/1/2020-12/31/9999  |
| BECTON DICKINSON   | 1/1/2015-12/31/2019  |
| BECTON DICKINSON   | 1/1/2020-12/31/9999  |
| BIODELIVERY SCIENCES INT   | 7/1/2019-12/31/9999  |
| BIOGEN   | 8/1/2011-12/31/2019  |
| BIOGEN   | 1/1/2020-12/31/9999  |
| BIOHAVEN PHARMACEUTICALS   | 4/1/2020-12/31/2022  |
| BOEHRINGER INGELHEIM   | 1/1/2017-12/31/2019  |
| BOEHRINGER INGELHEIM   | 1/1/2020-12/31/9999  |
| BRISTOL-MYERS SQUIBB   | 1/1/2017-12/31/2019  |
| BRISTOL-MYERS SQUIBB   | 1/1/2020-12/31/9999  |
| CELGENE CORP   | 1/1/2018-12/31/2019  |
| CELGENE CORP   | 1/1/2020-12/31/2020  |
| CHIESI USA   | 1/1/2020-12/31/9999  |
| CLOVIS ONCOLOGY INC  | 1/1/2020-12/31/2021  |
| COHERUS BIOSCIENCES  | 1/1/2020-12/31/9999  |
| COLLEGIUM PHARMACEUTICALS  | 7/1/2019-12/31/9999  |
| COVIS PHARMA   | 4/1/2019-12/31/2019  |
| COVIS PHARMA   | 1/1/2020-12/31/9999  |
| CUMBERLAND PHARMACEUTICALS   | 1/1/2016-12/31/2019  |
| DAIICHI SANKYO   | 1/1/2017-12/31/2019  |
| DERMIRA, INC   | 10/1/2018-12/31/2019 |

|  |                            |
|--|----------------------------|
| DERMIRA, INC   | 1/1/2020-12/31/9999        |
| DEXCOM   | 4/1/2014-12/31/2019        |
| DEXCOM   | 1/1/2020-12/31/9999        |
| DIGESTIVE CARE   | 1/1/2015-12/31/2019        |
| DIGESTIVE CARE   | 1/1/2020-12/31/9999        |
| DUCHESNAY USA, INC   | 1/1/2016-12/31/2019        |
| Anthem Supplemental Rebate Agreements in Place during SFY 2020 |                            |
| Manufacturer Name  | Contract Term              |
| DUCHESNAY USA, INC   | 1/1/2020-12/31/9999        |
| EGALET CORPORATION   | 7/1/2017-12/31/2019        |
| EGALET CORPORATION   | 1/1/2020-12/31/9999        |
| EISAI INC  | 1/1/2018-12/31/2019        |
| EISAI INC  | 1/1/2020-12/31/9999        |
| ELI LILLY & COMPANY  | 1/1/2019-12/31/2019        |
| ELI LILLY & COMPANY  | 1/1/2020-12/31/2021        |
| EMD SERONO   | 1/1/2019-<br>12/12/31/2021 |
| ENCORE DERMATOLOGY, INC  | 7/1/2019-12/31/2019        |
| ENDO PHARMACEUTICAL SOLUTIONS                                  | 1/1/2018-12/31/2019        |
| EXELIXIS INC   | 7/1/2017-12/31/2019        |
| EXELTIS USA DERMATOLOGY  | 1/1/2017-12/31/2019        |
| EXELTIS USA DERMATOLOGY  | 1/1/2020-12/31/9999        |
| EYEVANCE   | 10/1/2019-12/31/2019       |
| EYEVANCE   | 1/1/2020-12/31/2022        |
| FERRING  | 10/1/2013-12/31/2019       |
| FERRING  | 1/1/2020-12/31/9999        |
| FOUGERA PHARMACEUTICALS INC                                    | 1/1/2020-12/31/9999        |
| FRESENIUS USA  | 1/1/2019-12/31/2019        |
| FRESENIUS USA  | 1/1/2020-12/31/2021        |
| GALDERMA   | 7/1/2017-6/30/2021         |
| GENENTECH  | 1/1/2015-12/31/2019        |
| GENENTECH  | 1/1/2020-12/31/2021        |
| GILEAD SCIENCES INC  | 1/1/2009-12/31/2019        |
| GILEAD SCIENCES INC  | 1/1/2020-12/31/9999        |
| GLAXO SMITHKLINE   | 1/1/2019-12/31/2021        |
| GREENWICH BIOSCIENCES  | 1/1/2019-12/31/2019        |
| GREENWICH BIOSCIENCES  | 1/1/2020-12/31/2021        |
| GRIFOLS USA, LLC   | 1/1/2020-12/31/2022        |
| HORIZON PHARMA USA, INC  | 1/1/2014-12/31/2019        |
| HORIZON PHARMA USA, INC  | 1/1/2020-12/31/9999        |
| IMPAX PHARMACEUTICALS  | 1/1/2016-12/31/2019        |
| IMPAX PHARMACEUTICALS  | 1/1/2020-12/31/9999        |
| INDIVIOR   | 7/1/2019-12/31/9999        |



|  |                      |
|--|----------------------|
| INNOCUTIS HOLDINGS   | 4/1/2015-12/31/2019  |
| INNOCUTIS HOLDINGS   | 1/1/2020-12/31/9999  |
| INSMED   | 7/1/2019-12/31/9999  |
| INSYS THERAPEUTICS, INC  | 1/1/2015-12/31/9999  |
| IRONSHORE  | 10/1/2019-12/31/2019 |
| IRONSHORE  | 1/1/2020-12/31/9999  |
| Anthem Supplemental Rebate Agreements in Place during SFY 2020 |                      |
| Manufacturer Name  | Contract Term        |
| JAZZ   | 10/1/2019-12/31/2019 |
| JAZZ   | 4/1/2020-12/31/2022  |
| JOHNSON and JOHNSON  | 1/1/2017-12/31/2021  |
| KERYX BIOPHARMACEUTICALS, INC                                  | 1/1/2019-12/31/2019  |
| KERYX BIOPHARMACEUTICALS, INC                                  | 1/1/2020-12/31/9999  |
| KOWA PHARMACEUTICALS   | 4/1/2009-12/31/2019  |
| KOWA PHARMACEUTICALS   | 1/1/2020-12/31/2021  |
| KYOWA KIRIN  | 1/1/2020-6/30/2022   |
| LEO PHARMA, INC  | 4/1/2016-12/31/2019  |
| LEO PHARMA, INC  | 1/1/2020-12/31/2022  |
| LIFESCAN   | 1/1/2020-12/31/2021  |
| MALLINCKRODT   | 1/1/2019-12/31/2019  |
| MALLINCKRODT   | 10/1/2019-12/31/9999 |
| MANNKIND CORPORATION   | 1/1/2018-12/31/2019  |
| MANNKIND CORPORATION   | 1/1/2020-12/31/9999  |
| MAYNE PHARMA   | 4/1/2015-12/31/2019  |
| MAYNE PHARMA   | 1/1/2020-12/31/9999  |
| MEDA PHARMACEUTICALS   | 4/1/2011-12/31/2019  |
| MEDEXUS PHARMA   | 4/1/2015-12/31/2019  |
| MELINTA THERAPEUTICS INC                                       | 10/1/2018-12/31/2019 |
| MELINTA THERAPEUTICS INC                                       | 1/1/2020-12/31/9999  |
| MERCK & CO, INC  | 4/1/2017-12/31/2019  |
| MERCK & CO, INC  | 1/1/2020-12/31/2021  |
| MILLICENT  | 1/1/2020-7/31/2022   |
| MISSION  | 1/1/2019-12/31/2019  |
| MISSION  | 1/1/2020-12/31/9999  |
| MYLAN PHARMACEUTICALS INC                                      | 7/1/2015-12/31/2019  |
| MYLAN PHARMACEUTICALS INC                                      | 1/1/2020-12/31/2022  |
| NEOS THERAPEUTICS LP   | 5/1/2016-12/31/2019  |
| NEOS THERAPEUTICS LP   | 1/1/2020-12/31/9999  |
| NESTLE HEALTH SCIENCE  | 4/1/2014-12/31/2019  |
| NESTLE HEALTH SCIENCE  | 1/1/2020-12/31/9999  |
| NEUROCRINE BIOSCIENCES INC                                     | 1/1/2020-12/31/9999  |
| NOVARTIS   | 1/1/2019-12/31/2019  |
| NOVARTIS   | 1/1/2020-12/31/9999  |



| NOVEN THERAPEUTICS LLC   | 1/1/2019-12/31/2019  |
|--|----------------------|
| NOVEN THERAPEUTICS LLC   | 1/1/2020-12/31/9999  |
| NOVO NORDISK   | 7/1/2013-12/31/2021  |
| NOVO NORDISK   | 1/1/20-12/31/21      |
| OPKO PHARMACEUTICALS LLC                                       | 1/1/2017-12/31/2019  |
| Anthem Supplemental Rebate Agreements in Place during SFY 2020 |                      |
| Manufacturer Name  | Contract Term        |
| OPKO PHARMACEUTICALS LLC                                       | 1/1/2020-12/31/9999  |
| OPTINOSE US, INC   | 1/1/2018-12/31/2019  |
| OREXO  | 7/1/2019-12/31/2021  |
| OTSUKA   | 7/1/2016-12/31/2019  |
| OTSUKA   | 1/1/2020-12/31/9999  |
| PERNIX THERAPEUTICS, LLC                                       | 1/1/2016-12/31/2019  |
| PERNIX THERAPEUTICS, LLC                                       | 1/1/2020-12/31/9999  |
| PERRIGO  | 1/1/2016-12/31/2019  |
| PERRIGO  | 1/1/2020-12/31/9999  |
| PFIZER US PHARM  | 1/1/2019-12/31/2019  |
| PFIZER US PHARM  | 1/1/2020-12/31/9999  |
| PROCTER & GAMBLE   | 10/1/2003-12/31/2019 |
| PROMIUS PHARMA, INC  | 7/1/2016-12/31/2019  |
| PURDUE PHARMA  | 1/1/2014-12/31/2019  |
| PURDUE PHARMA  | 10/1/2019-12/31/9999 |
| RECKITT BENCKISER  | 4/1/2015-12/31/2019  |
| RECKITT BENCKISER  | 1/1/2020-12/31/9999  |
| RELYPSA, INC   | 1/1/2016-12/31/2019  |
| RELYPSA, INC   | 1/1/2020-3/31/2022   |
| RETROPHIN INC  | 7/1/2017-12/31/2019  |
| RETROPHIN INC  | 1/1/2020-12/31/9999  |
| ROCHE DIAGNOSTICS  | 1/1/2017-12/31/2019  |
| ROCHE DIAGNOSTICS  | 1/1/2020-12/31/2022  |
| SANDOZ INC   | 4/1/2015-09/30/2020  |
| SANDOZ INC   | 4/1/2020-12/31/9999  |
| SANOFI - AVENTIS   | 7/1/2013-12/31/2021  |
| SCILEX PHARMACEUTICALS INC                                     | 7/1/2019-12/31/9999  |
| SEBELA PHARMACEUTICALS INC                                     | 1/1/2017-12/31/2019  |
| SEBELA PHARMACEUTICALS INC                                     | 1/1/2020-12/31/9999  |
| SHIONOGI & COMPANY, INC  | 4/1/2016-12/31/2019  |
| SHIONOGI & COMPANY, INC  | 1/1/2020-12/31/2020  |
| SHIRE-RICHWOOD   | 1/1/2017-12/31/9999  |
| SHIRE-RICHWOOD   | 8/1/2019-08/31/2021  |
| SUN PHARMA INDUSTRIES INC                                      | 7/1/2018-12/31/2019  |
| SUN PHARMA INDUSTRIES INC                                      | 1/1/2020-12/31/2022  |
| SUNOVION   | 4/1/2012-12/31/2019  |

| SUNOVION   | 1/1/2020-12/31/9999  |
|--|----------------------|
| SUPERNUS PHARMACEUTICALS, INC                                  | 1/1/2017-12/31/2021  |
| SUPERNUS PHARMACEUTICALS, INC                                  | 1/1/2020-12/31/9999  |
| SYNERGY  | 4/1/2017-12/31/2019  |
| Anthem Supplemental Rebate Agreements in Place during SFY 2020 |                      |
| Manufacturer Name  | Contract Term        |
| TAKEDA   | 1/1/2017-12/31/2019  |
| TAKEDA   | 10/1/2019-12/31/9999 |
| TERSERA THERAPEUTICS   | 7/1/2018-12/31/2019  |
| TERSERA THERAPEUTICS   | 1/1/2020-12/31/9999  |
| TEVA   | 1/1/2019-12/31/2019  |
| TEVA   | 1/1/2020-12/31/9999  |
| THERAPEUTICSMD INC   | 7/1/2011-12/31/2019  |
| TOLMAR PHARMACEUTICALS INC                                     | 7/1/2017-03/31/2021  |
| TRIS PHARMA  | 7/1/2016-12/31/2019  |
| TRIS PHARMA  | 1/1/2020-12/31/9999  |
| TRIVIDIA HEALTH  | 1/1/2017-12/31/2019  |
| TRIVIDIA HEALTH  | 1/1/2020-12/31/2022  |
| UCB INC  | 1/1/2016-12/31/2019  |
| UCB INC  | 1/1/2020-12/31/9999  |
| UPSHER-SMITH   | 1/1/2020-12/31/9999  |
| US WORLDMEDS, LLC  | 1/1/2018-12/31/2019  |
| VALEANT PHARMACEUTICALS  | 4/1/2016-12/31/2019  |
| VALEANT PHARMACEUTICALS  | 1/1/2020-12/31/9999  |
| VERTICAL PHARMACEUTICALS                                       | 4/1/2016-12/31/2019  |
| VERTICAL PHARMACEUTICALS                                       | 1/1/2020-12/31/9999  |
| VIVUS  | 1/1/2020-12/31/9999  |
| WOMENS CHOICE PHARMACEUTICALS                                  | 10/1/2013-12/31/2019 |
| WOMENS CHOICE PHARMACEUTICALS                                  | 1/1/2020-12/31/9999  |
| XERIS  | 03/1/2020-12/31/9999 |

Table 3 below provides the value for each individual SRA. In order to meet the reporting requirements of SB378 and to maintain the confidentiality required by the SRAs, the agreements have been masked to prevent release of specific details. The numbering of the SRA is random and not based on the order manufacturers are listed in Table 2. Table 3 is sorted by descending contract value.

Table 3 Column Definitions:

- Supplemental Rebate Agreement ID — An alias identification used to identify the SRA without violating the terms of the confidentiality provisions.

- SFY 2020 Amount Anthem Medicaid Paid Providers for Drugs Under Contract During Contract Term — The amount Anthem Medicaid paid to the provider for drugs in SFY 2020 under contract during the term of the SRA.
  - Example: Drug “A” was subject to an SRA from 1/1/2019 to 12/31/2019 but not under a SRA in 2020. This column would include the amount Anthem Medicaid paid to providers for Drug “A” for claims paid from 7/1/2019 to 12/31/2019.
- Contract Value During SFY 2020 — The SRA invoiced during SFY 2020 to manufacturers for drugs subject to the SRA.

Table 3

| Anthem Supplemental Rebate Agreements in Place during Fiscal Year 2020 |  |  |
|--|--|--|
| Supplemental Rebate Agreement ID                                       | Fiscal Year 2020 Amount Anthem Medicaid Paid Providers for Drugs Under Contract During Contract Term | Contract Value During Fiscal Year 2020 |
| 1  | \$39,279.60  | \$0.00                                 |
| 2  | \$10,113,831.72  | \$917,103.95                           |
| 3  | \$7,506.86   | \$0.00                                 |
| 4  | \$614,421.70   | \$0.00                                 |
| 5  | \$108,891.53   | \$9,856.67                             |
| 6  | \$19,657.67  | \$0.00                                 |
| 7  | \$14,366.97  | \$0.00                                 |
| 8  | \$239,943.86   | \$0.00                                 |
| 9  | \$516,354.72   | \$53,850.66                            |
| 10   | \$3,018,763.99   | \$0.00                                 |
| 11   | \$238,619.39   | \$78,924.65                            |
| 12   | \$144,395.78   | \$0.00                                 |
| 13   | \$2,302,590.48   | \$483,712.50                           |
| 14   | \$28,409.02  | \$0.00                                 |
| 15   | \$12,709.56  | \$0.00                                 |
| 16   | \$159,923.29   | \$0.00                                 |
| 17   | \$276.91   | \$0.00                                 |
| 18   | \$1,767,257.14   | \$251,895.60                           |
| 19   | \$154,288.21   | \$0.00                                 |
| 20   | \$136,773.49   | \$0.00                                 |
| 21   | \$1,288,606.91   | \$0.00                                 |
| 22   | \$29,989.71  | \$0.00                                 |
| 23   | \$3,055,012.91   | \$153,633.08                           |
| 24   | \$14,112.28  | \$0.00                                 |
| 25   | \$34,114.95  | \$0.00                                 |
| 26   | \$45,555.64  | \$0.00                                 |

| 27   | \$347,260.38   | \$24,548.94                            |
|--|--|--|
| 28   | \$91,646.67  | \$0.00                                 |
| 29   | \$1,910,690.56   | \$21,151.79                            |
| 30   | \$16,541.40  | \$0.00                                 |
| Anthem Supplemental Rebate Agreements in Place during Fiscal Year 2020 |  |  |
| Supplemental Rebate Agreement ID                                       | Fiscal Year 2020 Amount Anthem Medicaid Paid Providers for Drugs Under Contract During Contract Term | Contract Value During Fiscal Year 2020 |
| 31   | \$3,488,074.43   | \$68,816.38                            |
| 32   | \$1,551,786.24   | \$152,038.97                           |
| 33   | \$414,311.24   | \$0.00                                 |
| 34   | \$880,370.01   | \$0.00                                 |
| 35   | \$925.97   | \$0.00                                 |
| 36   | \$24,652.14  | \$0.00                                 |
| 37   | \$12,299.55  | \$0.00                                 |
| 38   | \$181,809.13   | \$0.00                                 |
| 39   | \$4,562.04   | \$0.00                                 |
| 40   | \$0.00   | \$0.00                                 |
| 41   | \$54,853.42  | \$0.00                                 |
| 42   | \$60,188.02  | \$0.00                                 |
| 43   | \$77,393.69  | \$1,550.33                             |
| 44   | \$7,102.25   | \$0.00                                 |
| 45   | \$22,685.88  | \$0.00                                 |
| 46   | \$14,045.82  | \$0.00                                 |
| 47   | \$36,654.40  | \$0.00                                 |
| 48   | \$5,391,622.99   | \$195,093.64                           |
| 49   | \$781,126.83   | \$5,571.94                             |
| 50   | \$835.91   | \$0.00                                 |
| 51   | \$1,139.16   | \$0.00                                 |
| 52   | \$19,115.08  | \$0.00                                 |
| 53   | \$1,783.93   | \$0.00                                 |
| 54   | \$792.48   | \$0.00                                 |
| 55   | \$281,081.87   | \$110,418.96                           |
| 56   | \$1,487.93   | \$0.00                                 |
| 57   | \$62,351.58  | \$0.00                                 |
| 58   | \$20,851.81  | \$0.00                                 |
| 59   | \$1,250,879.51   | \$54,560.39                            |
| 60   | \$12,609,047.04  | \$0.00                                 |
| 61   | \$3,574,470.95   | \$245,747.06                           |
| 62   | \$94,838.59  | \$0.00                                 |
| 63   | \$6,577.98   | \$0.00                                 |
| 64   | \$79,327.59  | \$0.00                                 |

| 65   | \$21,392.00  | \$0.00                                 |
|--|--|--|
| 66   | \$62,885.73  | \$0.00                                 |
| 67   | \$773.11   | \$0.00                                 |
| Anthem Supplemental Rebate Agreements in Place during Fiscal Year 2020 |  |  |
| Supplemental Rebate Agreement ID                                       | Fiscal Year 2020 Amount Anthem Medicaid Paid Providers for Drugs Under Contract During Contract Term | Contract Value During Fiscal Year 2020 |
| 68   | \$6,800.30   | \$0.00                                 |
| 69   | \$4,724.09   | \$0.00                                 |
| 70   | \$113,807.46   | \$0.00                                 |
| 71   | \$5,285,861.05   | \$37,281.22                            |
| 72   | \$18,806.40  | \$0.00                                 |
| 73   | \$49,964.68  | \$0.00                                 |
| 74   | \$6,280.44   | \$0.00                                 |
| 75   | \$21,506.76  | \$0.00                                 |
| 76   | \$22,615.49  | \$0.00                                 |
| 77   | \$622,018.41   | \$0.00                                 |
| 78   | \$37,627.65  | \$0.00                                 |
| 79   | \$13,161.47  | \$0.00                                 |
| 80   | \$2,211.45   | \$0.00                                 |
| 81   | \$982.06   | \$0.00                                 |
| 82   | \$26,787.43  | \$0.00                                 |
| 83   | \$2,443,476.36   | \$55,002.69                            |
| 84   | \$524.24   | \$0.00                                 |
| 85   | \$783.73   | \$0.00                                 |
| 86   | \$11,663.62  | \$0.00                                 |
| 87   | \$5,777.51   | \$0.00                                 |
| 88   | \$3,601.35   | \$243.32                               |
| 89   | \$197,647.69   | \$0.00                                 |
| 90   | \$723,219.92   | \$585,663.32                           |
| 91   | \$948,829.98   | \$13,820.90                            |
| 92   | \$7,304.40   | \$0.00                                 |
| 93   | \$3,812,462.17   | \$286,275.06                           |
| 94   | \$18,015.32  | \$0.00                                 |
| 95   | \$477.11   | \$0.00                                 |
| 96   | \$6,785.63   | \$0.00                                 |
| 97   | \$2,450,146.76   | \$107,199.68                           |
| 98   | \$24,668.18  | \$0.00                                 |
| 99   | \$952.40   | \$0.00                                 |
| 100  | \$1,302,462.07   | \$0.00                                 |
| 101  | \$0.00   | \$0.00                                 |
| 102  | \$1,343.45   | \$0.00                                 |

| 103   | \$129,373.60  | \$0.00                                    |
|---|---|---|
| 104   | \$352.90  | \$62.07                                   |
| <b>Anthem Supplemental Rebate Agreements in Place during Fiscal Year 2020</b> |   |   |
| Supplemental<br>Rebate Agreement<br>ID  | Fiscal Year 2020 Amount Anthem<br>Medicaid Paid Providers for<br>Drugs Under Contract During<br>Contract Term | Contract Value During<br>Fiscal Year 2020 |
| 105   | \$5,101.34  | \$0.00                                    |
| 106   | \$29,771.81   | \$0.00                                    |
| 107   | \$11,372.75   | \$0.00                                    |
| 108   | \$38,269.46   | \$10,587.49                               |
| 109   | \$293,181.10  | \$0.00                                    |
| 110   | \$7,974.29  | \$0.00                                    |
| 111   | \$8,284.48  | \$0.00                                    |
| 112   | \$1,270,770.18  | \$10,462.13                               |
| 113   | \$19,851.01   | \$0.00                                    |
| 114   | \$2,428,950.19  | \$0.00                                    |
| 115   | \$102,204.12  | \$0.00                                    |
| 116   | \$4,005.60  | \$0.00                                    |
| 117   | \$416,093.29  | \$0.00                                    |
| 118   | \$6,393.89  | \$0.00                                    |
| 119   | \$260,764.15  | \$0.00                                    |
| 120   | \$116.54  | \$0.00                                    |
| 121   | \$13,286.44   | \$0.00                                    |
| 122   | \$18,901.73   | \$0.00                                    |
| 123   | \$31,179.25   | \$0.00                                    |
| 124   | \$8,444.59  | \$0.00                                    |
| 125   | \$741,627.45  | \$9,213.56                                |
| 126   | \$25,476.85   | \$0.00                                    |
| 127   | \$524.28  | \$0.00                                    |
| 128   | \$1,826.36  | \$816.56                                  |
| 129   | \$553.86  | \$0.00                                    |
| 130   | \$0.00  | \$0.00                                    |



# HEALTH PLAN OF NEVADA

A UnitedHealthcare Company

In compliance with the NRS 422.4025 adjustments effective 1/1/20, Health Plan of Nevada Medicaid has compiled the following report detailing the contractual rebate agreements and the blinded value of those rebates.

Health Plan of Nevada Medicaid had Supplemental Rebate Agreements (SRAs) in place with 46 manufacturers that were in effect during a portion of State Fiscal Year 2020 (July 1, 2019 – June 30, 2020) (hereinafter referred to as SFY 2020). Table 1 below summarizes the agreements:

**Table 1 Column Definitions:**

- Number of Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within SFY 2020.
- Contract Value During SFY 2020 - The supplemental rebate amount invoiced during SFY 2020 to manufacturers for drugs subject to SRAs.

Table 1

| Summary of Supplemental Rebate Agreements in Place during SFY 2020 |                                |
|--|--------------------------------|
| Number of Manufacturers Under Contract                             | Contract Value During SFY 2020 |
| 46   | \$8,603,399.40                 |

Table 2 below lists the SRAs in place during SFY 2020. The list is sorted alphabetically by manufacturer name.

**Table 2 Column Definitions:**

- Manufacturer Name - The name of the entity HPN has contracted with in the SRA
- Contract Term - The effective dates of the SRA during SFY 2020

Table 2

| Supplemental Rebate Agreements in Place during SFY 2020 |                       |
|---|-----------------------|
| Manufacturer Name                                       | Contract Term         |
| ABBOTT DC   | 7/1/2019 - 6/30/2020  |
| ABBVIE  | 7/1/2019 - 6/30/2020  |
| ACTELION  | 7/1/2019 - 12/30/2019 |
| ADAPT   | 7/1/2019 - 6/30/2020  |
| AERIE   | 7/1/2019 - 6/30/2020  |
| ALKERMES  | 7/1/2019 - 6/30/2020  |
| AMGEN   | 7/1/2019 - 6/30/2020  |
| ASEGUA  | 10/1/2019 - 6/30/2020 |
| ASTRA ZENECA  | 7/1/2019 - 6/30/2020  |
| BAUSCH HEALTH   | 4/1/2020 - 6/30/2020  |
| BECTON DICKINSON  | 7/1/2019 - 6/30/2020  |
| BIOGEN  | 7/1/2019 - 6/30/2020  |
| BMS   | 7/1/2019 - 6/30/2020  |
| BOEHRINGER INGLH  | 7/1/2019 - 6/30/2020  |
| CELGENE   | 7/1/2019 - 3/30/2020  |
| CHIESI  | 7/1/2019 - 6/30/2020  |

Good health takes a good plan.<sup>SM</sup>





HEALTH PLAN OF NEVADA  
A UnitedHealthcare Company

Table 2 continued

| Supplemental Rebate Agreements in Place during SFY 2020 |                       |
|---|-----------------------|
| Manufacturer Name                                       | Contract Term         |
| DEY   | 7/1/2019 - 6/30/2020  |
| ELI LILLY   | 7/1/2019 - 6/30/2020  |
| FERRING   | 7/1/2019 - 6/30/2020  |
| FRESENIUS KABI  | 7/1/2019 - 6/30/2020  |
| GALDERMA  | 7/1/2019 - 6/30/2020  |
| GILEAD  | 7/1/2019 - 6/30/2020  |
| GSK   | 7/1/2019 - 6/30/2020  |
| HIKMA   | 7/1/2019 - 6/30/2020  |
| INDIVIOR  | 7/1/2019 - 3/30/2020  |
| J&J   | 7/1/2019 - 6/30/2020  |
| LIFESCAN  | 7/1/2019 - 6/30/2020  |
| MERCK & CO INC  | 7/1/2019 - 6/30/2020  |
| NOVARTIS  | 7/1/2019 - 6/30/2020  |
| OTSUKA  | 7/1/2019 - 6/30/2020  |
| PERNIX  | 7/1/2019 - 6/30/2020  |
| PFIZER  | 7/1/2019 - 6/30/2020  |
| RADIUS HEALTH   | 7/1/2019 - 6/30/2020  |
| RELYPSA   | 7/1/2019 - 6/30/2020  |
| SANDOZ  | 7/1/2019 - 6/30/2020  |
| SANOFI-AVE  | 7/1/2019 - 6/30/2020  |
| SHIONOGI PHARMA   | 7/1/2019 - 6/30/2020  |
| SHIRE   | 7/1/2019 - 6/30/2020  |
| SMITH&NEPHEW  | 7/1/2019 - 6/30/2020  |
| SUNOVION  | 7/1/2019 - 6/30/2020  |
| TAKEDA  | 10/1/2019 - 6/30/2020 |
| TERSERA   | 7/1/2019 - 6/30/2020  |
| THER-RX   | 7/1/2019 - 6/30/2020  |
| UCB   | 7/1/2019 - 6/30/2020  |
| VALEANT   | 7/1/2019 - 6/30/2020  |
| VIIV  | 1/1/2020 - 6/30/2020  |

Good health takes a good plan.<sup>SM</sup>



**HEALTH PLAN OF NEVADA**  
A UnitedHealthcare Company

Table 3 below provides the value for each individual SRA. In order to meet the reporting requirements of SB378 and to maintain the confidentiality required by the SRAs, the agreements have been masked to prevent release of specific details. The numbering of the SRA is random and not based on the order manufacturers are listed in Table 2. Table 3 is sorted by descending contract value.

Table 3 Column Definitions:

- Supplemental Rebate Agreement ID - An alias identification used to identify the SRA without violating the terms of the confidentiality provisions.
- Contract Value During SFY 2020 - The SRA invoiced during SFY 2020 to manufacturers for drugs subject to the SRA.

Table 3

| Supplemental Rebate Agreements in Place during Fiscal Year 2020 |  |
|---|--|
| Supplemental Rebate Agreement ID                                | Contract Value During Fiscal Year 2020 |
| NVMCO HPN SRA 33  | \$ 2,539,161.84                        |
| NVMCO HPN SRA 46  | \$ 1,106,459.76                        |
| NVMCO HPN SRA 22  | \$ 802,725.01                          |
| NVMCO HPN SRA 4   | \$ 703,009.58                          |
| NVMCO HPN SRA 32  | \$ 555,136.40                          |
| NVMCO HPN SRA 27  | \$ 496,250.14                          |
| NVMCO HPN SRA 31  | \$ 341,971.86                          |
| NVMCO HPN SRA 37  | \$ 240,057.85                          |
| NVMCO HPN SRA 42  | \$ 238,364.70                          |
| NVMCO HPN SRA 6   | \$ 223,155.26                          |
| NVMCO HPN SRA 18  | \$ 209,040.40                          |
| NVMCO HPN SRA 19  | \$ 164,231.44                          |
| NVMCO HPN SRA 8   | \$ 155,118.53                          |
| NVMCO HPN SRA 21  | \$ 148,203.34                          |
| NVMCO HPN SRA 14  | \$ 110,205.60                          |
| NVMCO HPN SRA 5   | \$ 71,050.53                           |
| NVMCO HPN SRA 38  | \$ 66,880.00                           |
| NVMCO HPN SRA 17  | \$ 58,521.02                           |
| NVMCO HPN SRA 25  | \$ 51,896.52                           |
| NVMCO HPN SRA 36  | \$ 44,724.46                           |
| NVMCO HPN SRA 2   | \$ 41,322.76                           |
| NVMCO HPN SRA 9   | \$ 33,979.41                           |
| NVMCO HPN SRA 3   | \$ 27,432.34                           |
| NVMCO HPN SRA 30  | \$ 26,289.41                           |
| NVMCO HPN SRA 40  | \$ 24,551.72                           |

Good health takes a good plan.<sup>SM</sup>



HEALTH PLAN OF NEVADA  
A UnitedHealthcare Company

Table 3 continued

| Supplemental Rebate Agreements in Place during Fiscal Year 2020 |  |
|---|--|
| Supplemental Rebate Agreement ID                                | Contract Value During Fiscal Year 2020 |
| NVMCO HPN SRA 41  | \$ 22,805.47                           |
| NVMCO HPN SRA 26  | \$ 16,072.10                           |
| NVMCO HPN SRA 11  | \$ 12,060.77                           |
| NVMCO HPN SRA 35  | \$ 11,738.73                           |
| NVMCO HPN SRA 13  | \$ 11,719.62                           |
| NVMCO HPN SRA 45  | \$ 10,557.36                           |
| NVMCO HPN SRA 20  | \$ 9,269.38                            |
| NVMCO HPN SRA 7   | \$ 7,944.75                            |
| NVMCO HPN SRA 34  | \$ 4,583.32                            |
| NVMCO HPN SRA 28  | \$ 4,247.32                            |
| NVMCO HPN SRA 12  | \$ 3,964.94                            |
| NVMCO HPN SRA 29  | \$ 2,975.00                            |
| NVMCO HPN SRA 24  | \$ 2,431.12                            |
| NVMCO HPN SRA 10  | \$ 1,472.40                            |
| NVMCO HPN SRA 15  | \$ 695.95                              |
| NVMCO HPN SRA 23  | \$ 496.93                              |
| NVMCO HPN SRA 44  | \$ 313.32                              |
| NVMCO HPN SRA 1   | \$ 251.64                              |
| NVMCO HPN SRA 39  | \$ 31.42                               |
| NVMCO HPN SRA 43  | \$ 27.98                               |
| NVMCO HPN SRA 16  | \$ -                                   |

Good health takes a good plan.<sup>SM</sup>



2500 N. Buffalo Drive  
Suite 250  
Las Vegas, NV 89128

## **Supplemental Rebate Agreement Report State Fiscal Year 2020 (July 1, 2019 to June 30, 2020)**

The Medicaid Drug Rebate Program (MDRP) is a collaborative program between the Centers for Medicare & Medicaid Services (CMS), state Medicaid Programs, and participating drug manufacturers. It was authorized by Section 1927 of the Social Security Act and was created through the Omnibus Reconciliation Act in 1990. The MDRP reduces the overall cost of medications for many Nevada Medicaid recipients.

Over 600 manufacturers currently participate in the MDRP and they have signed national agreements to provide these cost-saving drug rebates. Manufacturers are required to have a national rebate agreement in place and, in exchange, the state Medicaid programs include most of the manufacturer's products as covered medications. Manufacturers not participating in the MDRP have their medications excluded from coverage and reimbursement in Medicaid programs.

The Affordable Care Act (ACA) increased the amount of rebates for both brand and generic drugs and extended the rebates to include outpatient drugs covered by Medicaid managed care organizations like SilverSummit Healthplan (SSHP); the MDRP previously only applied to Medicaid benefits offered directly from the State. The Medicaid rebate formula varies by type of drug and is set by law to ensure that the Medicaid program generally receives the lowest price.

The CMS Medicaid Drug Rebate system performs the needed URA (unit rebate amount) calculations and the consumer price index urban (CPI-U) is an integral part of the URA computation. The MDRP rebates are collected and shared between the state and federal government based on federal medical assistance percentages (FMAP).

Supplemental Rebate Agreements (SRAs) are rebate agreements that are in addition to, or supplemental to, the rebates that are part of the MDRP. The supplemental rebate program for Nevada Medicaid operates pursuant to Senate Bill 378, a law passed in 2019.

Supplemental rebates do not affect or reduce the rebates provided to the State of Nevada through the MDRP, but they do provide additional value to help health plans to manage drug costs. Drug manufacturers enter into SRAs with Pharmacy Benefit Managers (PBM). SSHP uses Envolve Pharmacy Solutions (EPS) and CVS Caremark for their PBM services. CVS Caremark contracts with manufacturers for SRAs for drugs on the SSHP Preferred Drug List. SSHP leverages the CVS Caremark SRAs to collect supplemental rebates and CVS Caremark manages the supplemental rebate invoicing and collection on behalf of SSHP.

SRAs with CVS Caremark vary in length depending on the manufacturer. Manufacturer SRAs create incentives to encourage placement of their drugs as preferred drug(s) on the health plan's Preferred

Drug List (PDL). Supplemental rebates calculations are specified in the individual contracts but the majority of contracts calculate rebates based on:

*Percentage of WAC:* set percentage of the drug’s published wholesale acquisition cost (WAC).

All SRAs are confidential and proprietary between CVS Caremark and the manufacturer.

**Table 1 - Summary of Supplemental Rebate Agreements in Place during SFY 2020**

| Number of Contracts | Number of Manufacturers Under Contract | SFY 2020 Amount Medicaid Paid Providers for Products Under Contract During Contract Term | Contract Value During SFY 2020 | Supplemental Rebate Percentage of Drug Spend for Contracted Products |
|---------------------|--|--|--------------------------------|--|
| 182                 | 106                                    | \$22,801,463.04  | \$945,758.73                   | 4.15%  |

Table 2 provides the list of SSHP’s applicable Supplemental Rebate Agreements in place during SFY 2020, sorted alphabetically by manufacturer. If a manufacturer had more than one Supplemental Rebate Agreement in place during SFY 2020, the contract term dates for each of those agreements are listed.

**Table 2 – Individual Supplemental Rebate Agreements in Place during SFY 2020**

| Vendor Name                 | Contract Effective Date | Contract Expiration Date |
|-----------------------------|-------------------------|--------------------------|
| ABBOTT DIABETES CARE        | 10/1/2013               | 12/31/2019               |
| ABBOTT DIABETES CARE        | 1/1/2020                | 12/31/2022               |
| ABBVIE INC                  | 1/1/2017                | 12/31/9999 (auto renew)  |
| ACTELION PHARMACEUTICALS    | 7/1/2015                | 12/31/2019               |
| ADAPT PHARMA INC            | 7/1/2016                | 12/31/2019               |
| ADAPT PHARMA INC            | 1/1/2020                | 12/31/9999 (auto renew)  |
| AERIE                       | 4/1/2018                | 12/31/2019               |
| AERIE                       | 1/1/2020                | 12/31/9999 (auto renew)  |
| AKORN, INC                  | 1/1/2014                | 12/31/2019               |
| AKORN, INC                  | 1/1/2020                | 12/31/2022               |
| AKRIMAX PHARMACEUTICALS LLC | 7/1/2017                | 12/31/2019               |
| ALKERMES INC                | 4/1/2016                | 12/31/2019               |
| ALKERMES INC                | 4/1/2020                | 12/31/2025               |
| ALLERGAN PHARM              | 1/1/2018                | 12/31/2019               |
| ALLERGAN PHARM              | 1/1/2020                | 12/31/9999 (auto renew)  |
| AMAG PHARMACEUTICALS, INC   | 7/1/2013                | 12/31/2019               |
| AMAG PHARMACEUTICALS, INC   | 1/1/2020                | 12/31/9999 (auto renew)  |
| AMARIN                      | 7/1/2015                | 12/31/2019               |
| AMARIN                      | 1/1/2020                | 12/31/9999 (auto renew)  |
| AMGEN                       | 4/1/2014                | 12/31/2019               |
| AMGEN                       | 1/1/2020                | 12/31/2022               |
| ANTARES PHARMA INC          | 4/1/2015                | 12/31/2019               |
| ANTARES PHARMA INC          | 1/1/2020                | 12/31/9999 (auto renew)  |

|                           |           |                         |
|---------------------------|-----------|-------------------------|
| AQUA PHARMACEUTICALS      | 4/1/2016  | 12/31/2019              |
| AQUA PHARMACEUTICALS      | 1/1/2020  | 3/31/2022               |
| ARBOR                     | 1/1/2012  | 12/31/2019              |
| ARBOR                     | 1/1/2020  | 12/31/2021              |
| ARKRAY USA INC            | 10/1/2013 | 12/31/2019              |
| ARKRAY USA INC            | 1/1/2020  | 12/31/2022              |
| ASEGUA                    | 1/1/2019  | 12/31/2019              |
| ASEGUA                    | 1/1/2020  | 12/31/9999 (auto renew) |
| ASSERTIO                  | 1/1/2019  | 12/31/2019              |
| ASSERTIO                  | 1/1/2020  | 12/31/9999 (auto renew) |
| ASTELLAS PHARMA US        | 1/1/2018  | 12/31/2019              |
| ASTELLAS PHARMA US        | 1/1/2020  | 12/31/9999 (auto renew) |
| ASTRA ZENECA              | 4/1/2004  | 12/31/2019              |
| ASTRA ZENECA              | 1/1/2020  | 12/31/9999 (auto renew) |
| AVION PHARMACEUTICALS     | 1/1/2013  | 12/31/2019              |
| AVION PHARMACEUTICALS     | 1/1/2020  | 12/31/9999 (auto renew) |
| BAYER                     | 1/1/2017  | 12/31/2019              |
| BAYER                     | 1/1/2020  | 12/31/2022              |
| BAYER DIAGNOSTICS         | 10/1/2013 | 12/31/2019              |
| BAYER DIAGNOSTICS         | 1/1/2020  | 12/31/9999 (auto renew) |
| BECTON DICKINSON          | 1/1/2015  | 12/31/2019              |
| BECTON DICKINSON          | 1/1/2020  | 12/31/9999 (auto renew) |
| BIODELIVERY SCIENCES INT  | 7/1/2019  | 12/31/9999 (auto renew) |
| BIOGEN                    | 8/1/2011  | 12/31/2019              |
| BIOGEN                    | 1/1/2020  | 12/31/9999 (auto renew) |
| BIOHAVEN PHARMACEUTICALS  | 4/1/2020  | 12/31/2022              |
| BOEHRINGER INGELHEIM      | 1/1/2017  | 12/31/2019              |
| BOEHRINGER INGELHEIM      | 1/1/2020  | 12/31/9999 (auto renew) |
| BRISTOL-MYERS SQUIBB      | 1/1/2017  | 12/31/2019              |
| BRISTOL-MYERS SQUIBB      | 1/1/2020  | 12/31/9999 (auto renew) |
| CELGENE CORP              | 1/1/2018  | 12/31/2019              |
| CELGENE CORP              | 1/1/2020  | 12/31/2020              |
| CELLTRION                 | 10/1/2019 | 12/31/2022              |
| COHERUS BIOSCIENCES       | 1/1/2019  | 12/31/2019              |
| COLLEGIUM PHARMACEUTICALS | 4/1/2016  | 9/30/2019               |
| COLLEGIUM PHARMACEUTICALS | 7/1/2019  | 12/31/9999 (auto renew) |
| COVIS PHARMA              | 4/1/2019  | 12/31/2019              |
| COVIS PHARMA              | 1/1/2020  | 12/31/9999 (auto renew) |
| DAIICHI SANKYO            | 1/1/2017  | 12/31/2019              |
| DAIICHI SANKYO            | 10/1/2019 | 12/31/2019              |
| DERMIRA, INC              | 10/1/2018 | 12/31/2019              |
| DERMIRA, INC              | 1/1/2020  | 12/31/9999 (auto renew) |
| DEXCOM                    | 4/1/2014  | 12/31/2019              |
| DEXCOM                    | 1/1/2020  | 12/31/9999 (auto renew) |
| DUCHESNAY USA, INC        | 1/1/2016  | 12/31/2019              |
| DUCHESNAY USA, INC        | 1/1/2020  | 12/31/9999 (auto renew) |
| ELI LILLY & COMPANY       | 1/1/2019  | 12/31/2019              |

|                               |           |                         |
|-------------------------------|-----------|-------------------------|
| ELI LILLY & COMPANY           | 1/1/2020  | 12/31/2021              |
| EMD SERONO                    | 1/1/2019  | 12/31/2021              |
| EXELTIS USA DERMATOLOGY       | 1/1/2020  | 12/31/9999 (auto renew) |
| EYEVANCE                      | 1/1/2020  | 12/31/2022              |
| FERRING                       | 10/1/2013 | 12/31/2019              |
| FERRING                       | 1/1/2020  | 12/31/9999 (auto renew) |
| GALDERMA                      | 7/1/2007  | 6/30/2021               |
| GENENTECH                     | 1/1/2015  | 12/31/2019              |
| GENENTECH                     | 1/1/2020  | 12/31/2022              |
| GENESIS HEALTH TECHNOLOGIES   | 8/1/2017  | 12/31/2019              |
| GILEAD SCIENCES INC           | 1/1/2009  | 12/31/2019              |
| GILEAD SCIENCES INC           | 1/1/2020  | 12/31/9999 (auto renew) |
| GLAXO SMITHKLINE              | 1/1/2019  | 12/31/2021              |
| HORIZON PHARMA USA, INC       | 1/1/2014  | 12/31/2019              |
| HORIZON PHARMA USA, INC       | 1/1/2020  | 12/31/9999 (auto renew) |
| IMPAX PHARMACEUTICALS         | 1/1/2016  | 12/31/2019              |
| IMPAX PHARMACEUTICALS         | 1/1/2020  | 12/31/9999 (auto renew) |
| INDIVIOR                      | 7/1/2019  | 12/31/9999 (auto renew) |
| IRONSHORE                     | 1/1/2020  | 12/31/9999 (auto renew) |
| JOHNSON and JOHNSON           | 1/1/2017  | 12/31/2021              |
| KALA PHARMACEUTICALS INC      | 1/1/2020  | 12/31/9999 (auto renew) |
| KERYX BIOPHARMACEUTICALS, INC | 1/1/2019  | 12/31/2019              |
| KERYX BIOPHARMACEUTICALS, INC | 1/1/2020  | 12/31/9999 (auto renew) |
| KOWA PHARMACEUTICALS          | 4/1/2009  | 12/31/2019              |
| KOWA PHARMACEUTICALS          | 1/1/2020  | 12/31/2021              |
| LIFESCAN                      | 1/1/2020  | 12/31/2021              |
| MANNKIND CORPORATION          | 1/1/2018  | 12/31/2019              |
| MANNKIND CORPORATION          | 1/1/2020  | 12/31/9999 (auto renew) |
| MAYNE PHARMA                  | 4/1/2015  | 12/31/2019              |
| MAYNE PHARMA                  | 1/1/2020  | 12/31/9999 (auto renew) |
| MEDA PHARMACEUTICALS          | 4/1/2011  | 12/31/2019              |
| MEDEXUS PHARMA                | 4/1/2015  | 12/31/2019              |
| MEDEXUS PHARMA                | 1/1/2020  | 12/31/2021              |
| MELINTA THERAPEUTICS INC      | 10/1/2018 | 12/31/2019              |
| MELINTA THERAPEUTICS INC      | 1/1/2020  | 12/31/9999 (auto renew) |
| MERCK & CO, INC               | 4/1/2017  | 12/31/2019              |
| MERCK & CO, INC               | 1/1/2020  | 12/31/2021              |
| MISSION                       | 1/1/2019  | 12/31/2019              |
| MISSION                       | 1/1/2020  | 12/31/9999 (auto renew) |
| MYLAN PHARMACEUTICALS INC     | 7/1/2015  | 12/31/2019              |
| MYLAN PHARMACEUTICALS INC     | 1/1/2020  | 12/31/2022              |
| NEOS THERAPEUTICS LP          | 5/1/2016  | 12/31/2019              |
| NEOS THERAPEUTICS LP          | 1/1/2020  | 12/31/9999 (auto renew) |
| NESTLE HEALTH SCIENCE         | 1/1/2020  | 12/31/9999 (auto renew) |
| NEUROCRINE BIOSCIENCES INC    | 1/1/2020  | 12/31/9999 (auto renew) |
| NOVARTIS                      | 1/1/2019  | 12/31/2019              |
| NOVARTIS                      | 1/1/2020  | 12/31/9999 (auto renew) |



|                               |           |                         |
|-------------------------------|-----------|-------------------------|
| NOVEN THERAPEUTICS LLC        | 1/1/2019  | 12/31/2019              |
| NOVEN THERAPEUTICS LLC        | 1/1/2020  | 12/31/9999 (auto renew) |
| NOVO NORDISK                  | 7/1/2013  | 12/31/2021              |
| NOVO NORDISK                  | 1/1/2020  | 12/31/2021              |
| OPKO PHARMACEUTICALS LLC      | 1/1/2017  | 12/31/2019              |
| OPKO PHARMACEUTICALS LLC      | 1/1/2020  | 12/31/9999 (auto renew) |
| OREXO                         | 7/1/2019  | 12/31/2021              |
| OTSUKA                        | 7/1/2016  | 12/31/2019              |
| OTSUKA                        | 1/1/2020  | 12/31/9999 (auto renew) |
| PERNIX THERAPEUTICS, LLC      | 1/1/2016  | 12/31/2019              |
| PERNIX THERAPEUTICS, LLC      | 1/1/2020  | 12/31/9999 (auto renew) |
| PERRIGO                       | 1/1/2016  | 12/31/2019              |
| PERRIGO                       | 1/1/2020  | 12/31/9999 (auto renew) |
| PFIZER US PHARM               | 1/1/2019  | 12/31/2019              |
| PFIZER US PHARM               | 1/1/2020  | 12/31/9999 (auto renew) |
| PURDUE PHARMA                 | 1/1/2014  | 12/31/2019              |
| PURDUE PHARMA                 | 10/1/2019 | 12/31/9999 (auto renew) |
| RADIUS HEALTH INC             | 4/1/2017  | 12/31/2019              |
| RADIUS HEALTH INC             | 1/1/2020  | 12/31/9999 (auto renew) |
| RECKITT BENCKISER             | 4/1/2015  | 12/31/2019              |
| RECKITT BENCKISER             | 1/1/2020  | 12/31/9999 (auto renew) |
| ROCHE DIAGNOSTICS             | 1/1/2017  | 12/31/2019              |
| ROCHE DIAGNOSTICS             | 1/1/2020  | 12/31/2022              |
| SANDOZ INC                    | 4/1/2015  | 12/31/2019              |
| SANDOZ INC                    | 4/1/2020  | 12/31/9999 (auto renew) |
| SANOFI - AVENTIS              | 7/1/2013  | 12/31/2021              |
| SCILEX PHARMACEUTICALS INC    | 7/1/2019  | 12/31/9999 (auto renew) |
| SEBELA PHARMACEUTICALS INC    | 1/1/2017  | 12/31/2019              |
| SEBELA PHARMACEUTICALS INC    | 1/1/2020  | 12/31/9999 (auto renew) |
| SHIRE-RICHWOOD                | 1/1/2017  | 12/31/9999 (auto renew) |
| SUN PHARMA INDUSTRIES INC     | 7/1/2018  | 12/31/2019              |
| SUN PHARMA INDUSTRIES INC     | 1/1/2020  | 12/31/2022              |
| SUNOVION                      | 4/1/2012  | 12/31/2019              |
| SUNOVION                      | 1/1/2020  | 12/31/9999 (auto renew) |
| SUPERNUS PHARMACEUTICALS, INC | 1/1/2017  | 12/31/2021              |
| SUPERNUS PHARMACEUTICALS, INC | 1/1/2020  | 12/31/9999 (auto renew) |
| SYNERGY                       | 4/1/2017  | 12/31/2019              |
| TAKEDA                        | 1/1/2017  | 9/30/2019               |
| TAKEDA                        | 10/1/2019 | 12/31/9999 (auto renew) |
| TERSERA THERAPEUTICS          | 7/1/2018  | 12/31/2019              |
| TERSERA THERAPEUTICS          | 1/1/2020  | 12/31/9999 (auto renew) |
| TESARO, INC                   | 4/1/2016  | 9/30/2020               |
| TEVA                          | 1/1/2019  | 12/31/2019              |
| TEVA                          | 1/1/2020  | 12/31/9999 (auto renew) |
| THERAPEUTICSMD INC            | 1/1/2020  | 12/31/9999 (auto renew) |
| TOLMAR PHARMACEUTICALS INC    | 7/1/2017  | 3/31/2021               |
| TRIS PHARMA                   | 7/1/2016  | 12/31/2019              |

|                               |           |                         |
|-------------------------------|-----------|-------------------------|
| TRIS PHARMA                   | 1/1/2020  | 12/31/9999 (auto renew) |
| TRIVIDIA HEALTH               | 1/1/2017  | 12/31/2019              |
| TRIVIDIA HEALTH               | 1/1/2020  | 12/31/2022              |
| UCB INC                       | 1/1/2016  | 12/31/2019              |
| UCB INC                       | 1/1/2020  | 12/31/9999 (auto renew) |
| UPSHER-SMITH                  | 1/1/2020  | 12/31/9999 (auto renew) |
| US WORLDMEDS, LLC             | 1/1/2018  | 12/31/2019              |
| VALEANT PHARMACEUTICALS       | 4/1/2016  | 12/31/2019              |
| VALEANT PHARMACEUTICALS       | 1/1/2020  | 12/31/9999 (auto renew) |
| VELOXIS PHARMACEUTICALS       | 1/1/2020  | 12/31/9999 (auto renew) |
| VERTICAL PHARMACEUTICALS      | 4/1/2016  | 12/31/2019              |
| VERTICAL PHARMACEUTICALS      | 1/1/2020  | 12/31/9999 (auto renew) |
| VIVUS                         | 10/1/2013 | 12/31/2019              |
| VIVUS                         | 1/1/2020  | 12/31/9999 (auto renew) |
| WOMENS CHOICE PHARMACEUTICALS | 10/1/2013 | 12/31/2019              |
| WOMENS CHOICE PHARMACEUTICALS | 1/1/2020  | 12/31/9999 (auto renew) |

Table 3 provides the contract value for each manufacturer's Supplemental Rebate Agreement for SFY 2020, sorted from highest rebate value to lowest. To maintain confidentiality, the manufacturers' identities were replaced with a Supplemental Rebate Agreement ID number.

**Table 3 – Value of Each Individual Supplemental Rebate Agreement for SFY 2020**

| Supplemental Rebate Agreement ID | SFY 2020 Amount Medicaid Paid Providers for Products Under Contract During Contract Term | Contract Value During SFY 2020 |
|----------------------------------|--|--------------------------------|
| 1                                | \$2,298,868.50   | \$212,316.76                   |
| 2                                | \$139,478.58   | \$116,137.77                   |
| 3                                | \$540,204.31   | \$111,012.64                   |
| 4                                | \$637,473.45   | \$85,315.43                    |
| 5                                | \$1,523,110.45   | \$67,815.16                    |
| 6                                | \$693,767.38   | \$61,688.91                    |
| 7                                | \$732,949.25   | \$60,859.99                    |
| 8                                | \$1,526,926.67   | \$48,601.92                    |
| 9                                | \$103,586.67   | \$34,946.56                    |
| 10                               | \$1,180,978.41   | \$30,204.40                    |
| 11                               | \$1,114,503.01   | \$29,749.95                    |
| 12                               | \$232,464.00   | \$19,200.00                    |
| 13                               | \$645,446.87   | \$12,983.07                    |
| 14                               | \$424,047.48   | \$8,436.44                     |
| 15                               | \$920,956.09   | \$7,060.30                     |
| 16                               | \$23,752.41  | \$6,637.35                     |
| 17                               | \$242,055.69   | \$5,508.54                     |
| 18                               | \$439,326.29   | \$5,268.75                     |
| 19                               | \$155,674.77   | \$4,581.67                     |
| 20                               | \$16,445.26  | \$3,600.63                     |
| 21                               | \$35,135.45  | \$3,273.75                     |

|    |                |            |
|----|----------------|------------|
| 22 | \$313,645.39   | \$3,012.44 |
| 23 | \$5,927.88     | \$2,224.62 |
| 24 | \$20,269.23    | \$2,197.62 |
| 25 | \$50,394.16    | \$1,408.97 |
| 26 | \$2,723.95     | \$589.83   |
| 27 | \$9,504.44     | \$569.12   |
| 28 | \$810.95       | \$225.25   |
| 29 | \$6,238.93     | \$193.96   |
| 30 | \$1,661.66     | \$147.21   |
| 31 | \$77.88        | \$12.28    |
| 32 | \$9,834.58     | \$0.00     |
| 33 | \$10,623.67    | \$0.00     |
| 34 | \$4,660.02     | \$0.00     |
| 35 | \$66,213.91    | \$0.00     |
| 36 | \$29,519.62    | \$0.00     |
| 37 | \$1,914.26     | \$0.00     |
| 38 | \$7,051.25     | \$0.00     |
| 39 | \$19,140.53    | \$0.00     |
| 40 | \$30.74        | \$0.00     |
| 41 | \$34,576.48    | \$0.00     |
| 42 | \$180,856.69   | \$0.00     |
| 43 | \$1,203,963.13 | \$0.00     |
| 44 | \$5,589.25     | \$0.00     |
| 45 | \$100,944.63   | \$0.00     |
| 46 | \$4,481.98     | \$0.00     |
| 47 | \$72,813.08    | \$0.00     |
| 48 | \$24,975.14    | \$0.00     |
| 49 | \$4,929.98     | \$0.00     |
| 50 | \$268,574.24   | \$0.00     |
| 51 | \$0.00         | \$0.00     |
| 52 | \$46,001.29    | \$0.00     |
| 53 | \$423.14       | \$0.00     |
| 54 | \$27,180.81    | \$0.00     |
| 55 | \$5,423.86     | \$0.00     |
| 56 | \$10,717.63    | \$0.00     |
| 57 | \$4,970.27     | \$0.00     |
| 58 | \$54,333.88    | \$0.00     |
| 59 | \$234.62       | \$0.00     |
| 60 | \$85.87        | \$0.00     |
| 61 | \$2,637.12     | \$0.00     |
| 62 | \$8,080.33     | \$0.00     |
| 63 | \$368,243.71   | \$0.00     |
| 64 | \$276.36       | \$0.00     |
| 65 | \$3,762,388.24 | \$0.00     |
| 66 | \$36,255.72    | \$0.00     |
| 67 | \$31,798.64    | \$0.00     |
| 68 | \$71,337.03    | \$0.00     |

|                    |                        |                     |
|--------------------|------------------------|---------------------|
| 69                 | \$353.03               | \$0.00              |
| 70                 | \$258.14               | \$0.00              |
| 71                 | \$9,257.11             | \$0.00              |
| 72                 | \$4,063.46             | \$0.00              |
| 73                 | \$2,621.96             | \$0.00              |
| 74                 | \$1,869.11             | \$0.00              |
| 75                 | \$879.57               | \$0.00              |
| 76                 | \$2,145.96             | \$0.00              |
| 77                 | \$691.60               | \$0.00              |
| 78                 | \$6,548.43             | \$0.00              |
| 79                 | \$2,288.10             | \$0.00              |
| 80                 | \$43,202.88            | \$0.00              |
| 81                 | \$7,318.12             | \$0.00              |
| 82                 | \$1,014.78             | \$0.00              |
| 83                 | \$7,478.13             | \$0.00              |
| 84                 | \$337.60               | \$0.00              |
| 85                 | \$13,415.08            | \$0.00              |
| 86                 | \$292.02               | \$0.00              |
| 87                 | \$34,382.24            | \$0.00              |
| 88                 | \$3,881.94             | \$0.00              |
| 89                 | \$5,539.63             | \$0.00              |
| 90                 | \$926,762.92           | \$0.00              |
| 91                 | \$47,744.19            | \$0.00              |
| 92                 | \$401.89               | \$0.00              |
| 93                 | \$128,317.96           | \$0.00              |
| 94                 | \$4,608.79             | \$0.00              |
| 95                 | \$62,322.11            | \$0.00              |
| 96                 | \$546.07               | \$0.00              |
| 97                 | \$318.80               | \$0.00              |
| 98                 | \$297.43               | \$0.00              |
| 99                 | \$1,936.99             | \$0.00              |
| 100                | \$188,571.21           | \$0.00              |
| 101                | \$152.78               | \$0.00              |
| 102                | \$6,221.46             | \$0.00              |
| 103                | \$12,586.85            | \$0.00              |
| 104                | \$189.75               | \$0.00              |
| 105                | \$0.00                 | \$0.00              |
| 106                | \$753,157.79           | (\$22.56)           |
| <b>Total Value</b> | <b>\$22,801,463.04</b> | <b>\$945,758.73</b> |

*SilverSummit Healthplan is a managed care plan that delivers quality health insurance to the people of Nevada. Established in 2017, SilverSummit is committed to improving the health of its members through focused, compassionate, and coordinated care. SilverSummit's active community involvement reaches beyond physical and mental health. We are dedicated to improve the quality of life, one person at a time. SilverSummit Healthplan is a diversified healthcare organization that offers healthcare services through Nevada Medicaid, Medicare, and the Health Insurance Marketplace. For more information on SilverSummit, you may visit [www.silversummithealthplan.com](http://www.silversummithealthplan.com).*



## Nevada Medicaid Fee-for-Service Rebate Program

Nevada Medicaid receives rebates on prescription drugs under two different programs. The Federal Medicaid Drug Rebate Program (MDRP) provides for Federally mandated rebates. The Nevada Medicaid Supplemental Rebate Program (NMSRP), pursuant to paragraph (b) of subsection 1 in section 31.4 of Senate Bill 378. (SB378), provides for Nevada-specific rebates that are in addition, or supplement, the Federally mandated rebates.

Created by the Omnibus Reconciliation Act of 1990 (OBRA 1990), the MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. The National Drug Rebate Agreement (NDRA) is with the Secretary of the United States Department of Health and Human Services (HHS) and pharmaceutical manufacturers. The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal unit rebate amount (URA) are set out by Federal statute.

In addition to the Federal rebate under the NDRA, state Medicaid agencies have the availability to collect additional rebates from manufacturers (e.g., supplemental). As set out above, the supplemental rebate program for Nevada Medicaid operates pursuant to SB378. The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists.

The NMSRP has operated as single state supplemental rebate program since January 1, 2012. The SRAs are between the manufacturers and the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP). Generally, the SRAs are in effect for one calendar year beginning on January 1<sup>st</sup> and terminating on December 31<sup>st</sup>. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new NDCs (National Drug Code) released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31<sup>st</sup> end date such as a product moving to non-preferred status or to coincide with planned Silver State Scripts Board (SSSB) review.

During State Fiscal Year 2020, the rebates negotiated under the NMSRP only applied to Medicaid fee-for-service (FFS) utilization. The other entities, authorized under SB378 to participate in the Medicaid FFS PDL, did not elect to participate.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- “Percentage of WAC” - set percentage of the drug’s published wholesale acquisition cost (WAC).
- “GNUP” (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
  - In the event a drug’s WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
  - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a product is defined within a manufacturer’s SRA with Nevada Medicaid.

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing related terms and conditions.

Nevada Medicaid had seventy-one (71) SRAs in place that were in effect during a portion of State Fiscal Year 2020 (July 1, 2019 – June 30, 2020) (hereinafter referred to as SFY 2020). Table 1 below summarizes the agreements:

Table 1 Column Definitions:

- Number of Contracts - The count of signed SRAs that were in force during some period within SFY 2020.
- Number of Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within SFY 2020.
- SFY 2020 Amount Medicaid Paid Providers for Products Under Contract During Contract Term - The amount Medicaid paid to providers for drugs subject to a manufacturer’s SRA during SFY 2020.
  - Example: Drug “A” was subject to an SRA from 01/01/2019 to 12/31/2019 but not under an agreement in 2020. This column would include the amount Medicaid paid to providers for Drug “A” for claims paid from 07/01/19 to 12/31/19.
- Contract Value During SFY 2020 - The supplemental rebate amount invoiced during SFY 2020 to manufacturers for drugs subject to SRAs.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

| Summary of Supplemental Rebate Agreements in Place during SFY 2020 |  |  |                                |  |
|--|--|--|--------------------------------|--|
| Number of Contracts  | Number of Manufacturers Under Contract | SFY 2020 Amount Medicaid Paid Providers for Products Under Contract During Contract Term | Contract Value During SFY 2020 | Supplemental Rebate Percentage of Drug Spend for Contracted Products |
| 71   | 36                                     | \$53,466,912.33  | \$7,661,308.26                 | 14.3%  |

Table 2 below lists the SRAs in place during SFY 2020. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA
- Contract Term - The effective and termination dates of the SRA

Table 2

Supplemental Rebate Agreements in Place during SFY 2020

| Manufacturer Name                          | Contract Term         |
|--|-----------------------|
| ABBVIE US LLC                              | 1/1/2019 - 12/31/2019 |
| ABBVIE US LLC                              | 1/1/2020 - 12/31/2020 |
| AERIE PHARMACEUTICALS, INC.                | 1/1/2019 - 12/31/2019 |
| AERIE PHARMACEUTICALS, INC.                | 9/1/2019 - 12/31/2019 |
| AERIE PHARMACEUTICALS, INC.                | 1/1/2020 - 12/31/2020 |
| ALLERGAN USA, INC.                         | 1/1/2019 - 12/31/2019 |
| ALLERGAN USA, INC.                         | 1/1/2020 - 12/31/2020 |
| AMGEN USA, INC.                            | 1/1/2019 - 12/31/2019 |
| AMGEN USA, INC.                            | 8/1/2019 - 12/31/2019 |
| AMGEN USA, INC.                            | 1/1/2020 - 12/31/2020 |
| ARBOR PHARMACEUTICALS, LLC                 | 1/1/2019 - 12/31/2019 |
| ASEGUA THERAPEUTICS, LLC                   | 6/1/2019 - 12/31/2019 |
| ASEGUA THERAPEUTICS, LLC                   | 1/1/2020 - 12/31/2020 |
| ASTRAZENECA PHARMACEUTICALS LP             | 1/1/2019 - 12/31/2019 |
| ASTRAZENECA PHARMACEUTICALS LP             | 1/1/2020 - 12/31/2020 |
| BAYER HEALTHCARE, LLC                      | 1/1/2019 - 12/31/2019 |
| BAYER HEALTHCARE, LLC                      | 1/1/2020 - 12/31/2020 |
| BIOGEN IDEC U.S. CORPORATION               | 1/1/2019 - 12/31/2019 |
| BIOGEN IDEC U.S. CORPORATION               | 1/1/2020 - 12/31/2020 |
| BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 1/1/2019 - 12/31/2019 |



| Supplemental Rebate Agreements in Place during SFY 2020 |                       |
|---|-----------------------|
| Manufacturer Name                                       | Contract Term         |
| BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.              | 1/1/2020 - 12/31/2020 |
| BRISTOL-MYERS SQUIBB COMPANY                            | 1/1/2019 - 12/31/2019 |
| BRISTOL-MYERS SQUIBB COMPANY                            | 1/1/2020 - 12/31/2020 |
| CHIESI USA, INC.  | 1/1/2019 - 12/31/2019 |
| CHIESI USA, INC.  | 1/1/2020 - 12/31/2020 |
| DAIICHI SANKYO, INC.                                    | 1/1/2019 - 12/31/2019 |
| DAIICHI SANKYO, INC.                                    | 1/1/2020 - 9/30/2020  |
| DUCHESNAY USA   | 1/1/2019 - 12/31/2019 |
| DUCHESNAY USA   | 1/1/2020 - 12/31/2020 |
| EISAI INC   | 1/1/2019 - 12/31/2019 |
| EISAI INC   | 1/1/2020 - 12/31/2020 |
| ELI LILLY AND COMPANY                                   | 1/1/2019 - 12/31/2019 |
| ELI LILLY AND COMPANY                                   | 1/1/2020 - 12/31/2020 |
| GENZYME CORPORATION                                     | 1/1/2019 - 12/31/2019 |
| GENZYME CORPORATION                                     | 7/1/2019 - 12/31/2019 |
| GENZYME CORPORATION                                     | 1/1/2020 - 12/31/2020 |
| GILEAD SCIENCES, INC.                                   | 1/1/2019 - 12/31/2019 |
| GILEAD SCIENCES, INC.                                   | 1/1/2020 - 12/31/2020 |
| GLAXOSMITHKLINE LLC                                     | 1/1/2019 - 12/31/2019 |
| GLAXOSMITHKLINE LLC                                     | 1/1/2020 - 12/31/2020 |
| INDEPENDENCE PHARMACEUTICALS, LLC                       | 1/1/2019 - 12/31/2019 |
| INDEPENDENCE PHARMACEUTICALS, LLC                       | 1/1/2020 - 12/31/2020 |
| INDIVIOR INC.   | 1/1/2019 - 12/31/2019 |
| INDIVIOR INC.   | 6/1/2019 - 12/31/2019 |
| INDIVIOR INC.   | 1/1/2020 - 12/31/2020 |
| JANSSEN PHARMACEUTICALS, INC.                           | 1/1/2019 - 12/31/2019 |
| MERCK SHARP & DOHME CORP.                               | 1/1/2019 - 12/31/2019 |
| NOVARTIS PHARMACEUTICALS CORPORATION                    | 1/1/2019 - 12/31/2019 |
| NOVARTIS PHARMACEUTICALS CORPORATION                    | 1/1/2020 - 12/31/2020 |
| NOVO NORDISK INC.                                       | 1/1/2019 - 12/31/2019 |
| NOVO NORDISK INC.                                       | 1/1/2020 - 12/31/2020 |
| OREXO US, INC.  | 1/1/2019 - 12/31/2019 |
| OTSUKA AMERICA PHARMACEUTICAL, INC.                     | 1/1/2019 - 12/31/2019 |
| OTSUKA AMERICA PHARMACEUTICAL, INC.                     | 1/1/2020 - 12/31/2020 |
| PARAPRO, LLC  | 1/1/2020 - 12/31/2020 |
| PARI RESPIRATORY EQUIPMENT, INC.                        | 1/1/2019 - 12/31/2019 |
| PARI RESPIRATORY EQUIPMENT, INC.                        | 1/1/2020 - 12/31/2020 |
| PFIZER INC  | 1/1/2019 - 12/31/2019 |

| Supplemental Rebate Agreements in Place during SFY 2020 |                       |
|---|-----------------------|
| Manufacturer Name                                       | Contract Term         |
| PFIZER INC  | 1/1/2020 - 12/31/2020 |
| SANOFI-AVENTIS US LLC                                   | 1/1/2019 - 12/31/2019 |
| SANOFI-AVENTIS US LLC                                   | 1/1/2020 - 12/31/2020 |
| SHIRE US, INC.  | 1/1/2019 - 12/31/2019 |
| SHIRE US, INC.  | 1/1/2020 - 12/31/2020 |
| SUNOVION PHARMACEUTICALS INC.                           | 1/1/2019 - 12/31/2019 |
| SUNOVION PHARMACEUTICALS INC.                           | 2/1/2019 - 12/31/2019 |
| SUNOVION PHARMACEUTICALS INC.                           | 1/1/2020 - 12/31/2020 |
| TEVA PHARMACEUTICALS USA, INC.                          | 6/1/2020 - 3/31/2021  |
| TRIS PHARMA   | 1/1/2019 - 12/31/2019 |
| TRIS PHARMA   | 1/1/2020 - 12/31/2020 |
| UCB, INC.   | 1/1/2019 - 12/31/2019 |
| UCB, INC.   | 1/1/2020 - 12/31/2020 |

Table 3 below provides the value for each individual SRA. In order to meet the reporting requirements of SB378 and to maintain the confidentiality required by the SRAs, the agreements have been masked to prevent release of specific details. The numbering of the SRA is random and not based on the order manufacturers are listed in Table 2. Table 3 is sorted by descending contract value.

Table 3 Column Definitions:

- Supplemental Rebate Agreement ID - An alias identification used to identify the SRA without violating the terms of the confidentiality provisions.
- SFY 2020 Amount Medicaid Paid Providers for Drugs Under Contract During Contract Term - The amount Medicaid paid to the provider for drugs in SFY 2020 under contract during the term of the SRA.
  - Example: Drug “A” was subject to a SRA from 01/01/2019 to 12/31/2019 but not under a SRA in 2020. This column would include the amount Medicaid paid to providers for Drug “A” for claims paid from 07/01/2019 to 12/31/19.
- Contract Value During SFY 2020 - The SRA invoiced during SFY 2020 to manufacturers for drugs subject to the SRA.

Table 3

| Supplemental Rebate Agreements in Place during Fiscal Year 2020 |   |  |
|---|---|--|
| Supplemental Rebate Agreement ID                                | Fiscal Year 2020 Amount Medicaid Paid Providers for Drugs Under Contract During Contract Term | Contract Value During Fiscal Year 2020 |
| NVM SRA 7   | \$5,499,021.61  | \$2,331,283.07                         |
| NVM SRA 53  | \$3,967,535.00  | \$1,305,257.55                         |
| NVM SRA 39  | \$920,295.17  | \$320,244.42                           |
| NVM SRA 51  | \$1,982,580.44  | \$298,443.12                           |
| NVM SRA 26  | \$996,696.72  | \$285,791.23                           |
| NVM SRA 22  | \$1,961,484.86  | \$271,925.43                           |
| NVM SRA 3   | \$1,585,993.42  | \$236,081.34                           |
| NVM SRA 6   | \$3,865,104.60  | \$229,157.66                           |
| NVM SRA 21  | \$515,390.12  | \$223,863.64                           |
| NVM SRA 63  | \$576,908.48  | \$155,463.21                           |
| NVM SRA 23  | \$3,082,181.91  | \$150,348.73                           |
| NVM SRA 14  | \$688,752.58  | \$144,287.28                           |
| NVM SRA 44  | \$1,517,890.55  | \$128,648.69                           |
| NVM SRA 48  | \$1,189,177.06  | \$127,018.84                           |
| NVM SRA 10  | \$209,187.70  | \$109,944.64                           |
| NVM SRA 12  | \$681,055.72  | \$101,812.58                           |
| NVM SRA 24  | \$503,965.42  | \$96,638.98                            |
| NVM SRA 55  | \$1,489,287.80  | \$88,394.16                            |
| NVM SRA 62  | \$644,776.82  | \$86,950.18                            |
| NVM SRA 16  | \$759,334.42  | \$85,426.22                            |
| NVM SRA 45  | \$495,229.52  | \$74,443.82                            |
| NVM SRA 17  | \$1,815,121.95  | \$74,319.78                            |
| NVM SRA 15  | \$879,030.12  | \$65,930.03                            |
| NVM SRA 32  | \$863,577.29  | \$53,760.54                            |
| NVM SRA 37  | \$1,993,161.04  | \$53,026.39                            |
| NVM SRA 2   | \$993,866.56  | \$49,655.48                            |
| NVM SRA 40  | \$164,914.69  | \$41,746.35                            |
| NVM SRA 36  | \$395,606.69  | \$38,448.67                            |
| NVM SRA 60  | \$856,755.57  | \$36,383.44                            |
| NVM SRA 71  | \$1,390,029.99  | \$35,195.01                            |
| NVM SRA 18  | \$200,621.44  | \$34,668.86                            |
| NVM SRA 31  | \$76,737.83   | \$28,594.18                            |
| NVM SRA 41  | \$1,306,120.76  | \$28,165.26                            |
| NVM SRA 46  | \$937,073.90  | \$28,075.43                            |
| NVM SRA 33  | \$1,854,627.69  | \$26,421.86                            |

| Supplemental Rebate Agreements in Place during Fiscal Year 2020 |   |  |
|---|---|--|
| Supplemental Rebate Agreement ID                                | Fiscal Year 2020 Amount Medicaid Paid Providers for Drugs Under Contract During Contract Term | Contract Value During Fiscal Year 2020 |
| NVM SRA 56  | \$102,787.33  | \$18,852.02                            |
| NVM SRA 11  | \$1,345,310.84  | \$18,445.86                            |
| NVM SRA 5   | \$76,230.23   | \$17,320.12                            |
| NVM SRA 61  | \$423,105.63  | \$17,252.72                            |
| NVM SRA 68  | \$80,546.96   | \$16,082.98                            |
| NVM SRA 47  | \$236,541.37  | \$15,494.45                            |
| NVM SRA 49  | \$136,590.49  | \$15,380.70                            |
| NVM SRA 29  | \$129,945.12  | \$14,526.70                            |
| NVM SRA 35  | \$284,249.61  | \$12,234.30                            |
| NVM SRA 57  | \$126,744.91  | \$10,156.81                            |
| NVM SRA 9   | \$671,552.61  | \$10,140.98                            |
| NVM SRA 67  | \$298,294.00  | \$8,893.99                             |
| NVM SRA 69  | \$142,194.47  | \$8,695.91                             |
| NVM SRA 20  | \$34,817.45   | \$7,932.02                             |
| NVM SRA 59  | \$80,260.39   | \$3,815.40                             |
| NVM SRA 1   | \$160,654.24  | \$3,569.56                             |
| NVM SRA 19  | \$337,623.49  | \$3,259.67                             |
| NVM SRA 66  | \$12,012.56   | \$3,057.09                             |
| NVM SRA 27  | \$10,075.30   | \$2,214.18                             |
| NVM SRA 58  | \$14,190.30   | \$2,166.70                             |
| NVM SRA 52  | \$7,798.66  | \$2,047.94                             |
| NVM SRA 28  | \$4,069.44  | \$1,766.87                             |
| NVM SRA 65  | \$4,420.16  | \$871.10                               |
| NVM SRA 64  | \$51,709.50   | \$531.77                               |
| NVM SRA 13  | \$11,607.60   | \$328.70                               |
| NVM SRA 4   | \$1,102.44  | \$294.72                               |
| NVM SRA 42  | \$15,136.58   | \$158.93                               |
| NVM SRA 38  | \$1,119,192.83  | \$0.00                                 |
| NVM SRA 50  | \$689,052.38  | \$0.00                                 |
| NVM SRA 25  | \$0.00  | \$0.00                                 |
| NVM SRA 30  | \$0.00  | \$0.00                                 |
| NVM SRA 34  | \$0.00  | \$0.00                                 |
| NVM SRA 43  | \$0.00  | \$0.00                                 |
| NVM SRA 54  | \$0.00  | \$0.00                                 |
| NVM SRA 70  | \$0.00  | \$0.00                                 |
| NVM SRA 8   | \$0.00  | \$0.00                                 |